Abstract:6059 Background: In the intensity-modulated radiation therapy (IMRT) era, xerostomia remains one of the most common radiation-induced toxicities in nasopharyngeal carcinoma (NPC) patients. We first proposed the superficial parotid lobe–sparing IMRT (SPLS-IMRT) technique in NPC, which has been proved to significantly reduce the mean doses of bilateral entire parotid glands and superficial parotid lobes. To further validate its clinical benefits, we conducted a prospective phase II randomized controlled study to compare the incidence of xerostomia in NPC patients treated with SPLS-IMRT and conventional IMRT (C-IMRT). Methods: Patients with histologically confirmed NPC who met the eligibility criteria were randomly assigned in a 1:1 ratio to receive either SPLS-IMRT or C-IMRT. The V36 (the percentage volume receiving a dose of 36 Gy) of the entire parotid gland was constrained to be less than 40% in both groups. Additionally, V26 (the percentage volume receiving a dose of 26 Gy) of the superficial parotid lobe was constrained to be less than 30% in the SPLS-IMRT group. The primary endpoint was the incidence of xerostomia at 12 months post-IMRT. The secondary endpoints included the xerostomia questionnaire (XQ) score, unstimulated salivary flow rate (USFR), stimulated salivary flow rate (SSFR), and survival outcomes. Results: From January 2018 to September 2018, 90 patients were enrolled (45 per group). Eighty-two patients were included for xerostomia analysis (42 in the SPLS-IMRT group and 40 in the C-IMRT group). At 12 months post-IMRT, the incidence of xerostomia in the SPLS-IMRT group was significantly lower than that in the C-IMRT group (83.4% vs. 95.0%; P = 0.007), especially the grade 3 xerostomia (0% vs. 12.5%; P < 0.001). However, the median change in XQ score (XQ change ) was similar between the two groups (11.9 points vs. 14.1 points; P = 0.194). Moreover, there was a significantly higher median fractional USFR (0.67 vs. 0.35; P = 0.024) and SSFR (0.66 vs. 0.32; P = 0.021) in the SPLS-IMRT group than the C-IMRT group. All 90 patients were included for survival analysis. With a median follow-up time of 37.8 months (IQR, 33.9–38.5 months), the 3-year locoregional relapse-free survival, distant metastasis-free survival, and overall survival in the SPLS-IMRT and C-IMRT groups were 92.5% vs. 90.9% (hazard ratio [HR], 1.84; P = 0.477), 83.8% vs. 81.7% (HR, 1.13; P = 0.816), and 88.9% vs. 88.2% (HR, 0.96; P = 0.949), respectively. Conclusions: SPLS-IMRT significantly reduced the incidence of xerostomia at 12 months post-IMRT in NPC by recovering parotid gland function earlier than C-IMRT, without compromising survivals. Phase III clinical trials are needed to confirm this result. Clinical trial information: NCT05020067.

Submandibular salivary gland transfer for the prevention of radiation-induced xerostomia in patients with nasopharyngeal carcinoma: 5-Year outcomes.

Oncological Safty Evaluation of Submandibular Salivary Gland Transfer Prevents Radiation-Induced Xerostomia in the Patients with Nasopharyngeal Carcinoma

[Primary Effect of Submandibular Salivary Gland Transfer in Preventing Radiation-Induced Xerostomia of Nasopharyngeal Carcinoma].

Oncological Outcome of Patients with Salivary Gland Cancer Treated with Surgery and Postoperative Intensity-Modulated Radiotherapy: a Retrospective Study

Submandibular Gland Transfer Prevents Radiation-Induced Xerostomia

Clinical Research on Submandibular Gland Transposition Intervening Acute Radiation-Induced Oral Mucosal Reaction and Xerostomia

Submandibular Gland Transfer for the Prevention of Postradiation Xerostomia in Patients with Head and Neck Cancer: A Systematic Review and Meta-Analysis

Impact of Salivary Gland Dosimetry on Post-Imrt Recovery of Saliva Output and Xerostomia Grade for Head-and-neck Cancer Patients Treated with or Without Contralateral Submandibular Gland Sparing: a Longitudinal Study.

Salivary gland function in nasopharyngeal carcinoma before and late after intensity-modulated radiotherapy evaluated by dynamic diffusion-weighted MR imaging with gustatory stimulation

Reducing Xerostomia by Comprehensive Protection of Salivary Glands in Intensity-Modulated Radiation Therapy with Helical Tomotherapy Technique for Head-and-Neck Cancer Patients: A Prospective Observational Study.

Effects of an integrated supportive program on xerostomia and saliva characteristics in patients with head and neck cancer radiated with a low dose to the major salivary glands: a randomized controlled trial

Dosimetry of Submandibular Glands on Xerostomia for Nasopharyngeal Carcinoma

The Impact of Submandibular Glands Protection on Xerostomia As Monitored by Diffusion-Weighted Imaging in Nasopharyngeal Carcinoma Patients.

Magnetic Resonance Sialography for Investigating Major Salivary Gland Duct System after Intensity-Modulated Radiotherapy of Nasopharyngeal Carcinoma

Protective effect of intensity-modulated radiation therapy on salivary gland function in nasopharyngeal carcinoma patients

Experimental Study of Rabbit Submandibular Salivary Gland Transfer Prevents Radiation-Induced Xerostomia

Sparing Submandibular Gland to Alleviating Acute Xerostomia in Patients with Nasopharyngeal Carcinoma Treated with Helical Tomotherapy: Evaluation by Diffusion Kurtosis Imaging

Impact on xerostomia for patients with nasopharyngeal carcinoma treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.

The Effects of an Integrated Supportive Programme on Xerostomia and Salivary Characteristics in Patients with Head and Neck Cancer Undergoing Radiotherapy: a Randomized Controlled Trial

Submandibular gland transfer into the temporal fossa in patients with oral squamous cell carcinoma: A viable option to prevent radiation-induced xerostomia

Survey on Xerostomia after radiotherapy for the nasopharyngeal carcinoing patients